Alexander Biederstädt

Alexander Biederstädt, MD, is a Junior Group Leader at the Technical University of Munich, specializing in adoptive cell therapy with a focus on CRISPR-enabled immune cell engineering and preclinical development of synthetic biology-engineered immune cells. Experience includes extensive clinical work in hematology and medical oncology, serving as a deputy PI in numerous clinical trials at MD Anderson Cancer Center, where involvement in advancing CAR-NK cell immunotherapies occurred. Alexander played a pivotal role in the CAR-T program, contributing to the certification of multiple CAR-T products and optimizing GMP manufacturing processes. Prior to this, engagement with McKinsey & Company involved transforming organizational structures within global pharmaceutical companies. Education includes a Doctor of Medicine degree from Ludwig-Maximilians-Universität München.